Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function
This compilation focuses on recent advances in the molecular and cellular understandingof neuromuscular biology, and the treatment of neuromuscular disease.These advances are at the forefront of modern molecular methodologies, oftenintegrating across wet-lab cell and tissue models, dry-lab computati...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (318 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04710nam-a2201441z--4500 | ||
|---|---|---|---|
| 001 | 993546289804498 | ||
| 005 | 20231214133630.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202201s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000044814 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/76949 | ||
| 035 | |a (EXLCZ)995400000000044814 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Duddy, William |4 edt | |
| 245 | 1 | 0 | |a Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function |
| 246 | |a Understanding Neuromuscular Health and Disease | ||
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (318 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This compilation focuses on recent advances in the molecular and cellular understandingof neuromuscular biology, and the treatment of neuromuscular disease.These advances are at the forefront of modern molecular methodologies, oftenintegrating across wet-lab cell and tissue models, dry-lab computational approaches,and clinical studies. The continuing development and application ofmultiomics methods offer particular challenges and opportunities in the field,not least in the potential for personalized medicine. | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 653 | |a LMNA | ||
| 653 | |a Emery-Dreifuss muscular dystrophy | ||
| 653 | |a Omics | ||
| 653 | |a ALS | ||
| 653 | |a MND | ||
| 653 | |a ALS variants | ||
| 653 | |a genotype-phenotype | ||
| 653 | |a ALS genes | ||
| 653 | |a FSHD | ||
| 653 | |a DUX4 | ||
| 653 | |a transcription | ||
| 653 | |a muscle | ||
| 653 | |a regulation | ||
| 653 | |a spinal muscular atrophy | ||
| 653 | |a adult patients | ||
| 653 | |a disease heterogeneity | ||
| 653 | |a Nusinersen | ||
| 653 | |a disease modifiers | ||
| 653 | |a functional outcomes | ||
| 653 | |a biomarkers | ||
| 653 | |a epigenetic changes | ||
| 653 | |a -omics approaches | ||
| 653 | |a oxidative stress | ||
| 653 | |a mitochondria dysfunction | ||
| 653 | |a axonal transport | ||
| 653 | |a autophagy | ||
| 653 | |a endocytosis | ||
| 653 | |a secretion | ||
| 653 | |a excitotoxicity | ||
| 653 | |a RNA metabolism | ||
| 653 | |a Duchenne muscular dystrophy (DMD) | ||
| 653 | |a exon-skipping therapies | ||
| 653 | |a next-generation sequencing (NGS) | ||
| 653 | |a Sanger sequencing | ||
| 653 | |a multiplex ligation probe amplification (MLPA) | ||
| 653 | |a multiplex polymerase chain reaction (PCR) | ||
| 653 | |a comparative genomic hybridization array (CGH) | ||
| 653 | |a viltolarsen | ||
| 653 | |a eteplirsen | ||
| 653 | |a golodirsen | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a SNP | ||
| 653 | |a DMARD | ||
| 653 | |a methotrexate | ||
| 653 | |a pharmacogenomics | ||
| 653 | |a Duchenne muscular dystrophy | ||
| 653 | |a pharmacodynamic biomarkers | ||
| 653 | |a prednisone | ||
| 653 | |a deflazacort | ||
| 653 | |a glucocorticoids | ||
| 653 | |a corticosteroids | ||
| 653 | |a safety | ||
| 653 | |a neuromuscular diseases | ||
| 653 | |a translational research | ||
| 653 | |a disease models | ||
| 653 | |a precision medicine | ||
| 653 | |a miRNA | ||
| 653 | |a proteomics | ||
| 653 | |a calprotectin | ||
| 653 | |a dystrophy | ||
| 653 | |a Becker muscular dystrophy | ||
| 653 | |a dystrophinopathy | ||
| 653 | |a genotype-phenotype correlations | ||
| 653 | |a Canadian Neuromuscular Disease Registry | ||
| 653 | |a reading frame rule | ||
| 653 | |a dystrophin | ||
| 653 | |a multiple logistic regression analysis | ||
| 653 | |a exon skipping therapy | ||
| 653 | |a Amyotrophic Lateral Sclerosis | ||
| 653 | |a machine learning | ||
| 653 | |a genome-wide association studies | ||
| 653 | |a GWAS | ||
| 653 | |a genomics | ||
| 653 | |a ALS pathology | ||
| 653 | |a gene prioritization | ||
| 653 | |a AAV | ||
| 653 | |a genetic neuromuscular disorders | ||
| 653 | |a gene therapy | ||
| 653 | |a clinical trials | ||
| 653 | |a toxicity | ||
| 653 | |a SMA | ||
| 653 | |a DMD | ||
| 653 | |a XLMTM | ||
| 653 | |a facioscapulohumeral dystrophy | ||
| 653 | |a TALEN | ||
| 653 | |a CRISPR-Cas9 | ||
| 653 | |a gene editing | ||
| 653 | |a polyadenylation | ||
| 653 | |a D4Z4 | ||
| 653 | |a duchenne muscular dystrophy (DMD) | ||
| 653 | |a becker muscular dystrophy (BMD) | ||
| 653 | |a exon skipping | ||
| 653 | |a skip-equivalent deletions | ||
| 776 | |z 3-0365-1622-0 | ||
| 776 | |z 3-0365-1621-2 | ||
| 700 | 1 | |a Duguez, Stephanie |4 edt | |
| 700 | 1 | |a Duddy, William |4 oth | |
| 700 | 1 | |a Duguez, Stephanie |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:59:57 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338159530004498&Force_direct=true |Z 5338159530004498 |b Available |8 5338159530004498 | ||